Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
Cancer Science|November 12, 2022
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancerTakayuki Yoshino, Thierry Andre, Tae Won Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)Guillem Argilés, Nuria Mulet, Manuel Valladares-Ayerbes, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer RegistryAlberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, et al.
Current Problems in Cardiology|June 26, 2022
Worsening heart failure in Colombia: Analysis from RECOLFACA registryClara Saldarriaga, Juan Esteban Gómez-Mesa, Alex Arnulfo Rivera Toquica, et al.
The New England Journal of Medicine|December 2, 2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal CancerThierry André, Kai-Keen Shiu, Tae Won Kim, et al.
Oncotarget|September 15, 2017
GNP-GAPDH1-22 nanovaccines prevent neonatal listeriosis by blocking microglial apoptosis and bacterial disseminationRicardo Calderon-Gonzalez, Elisabet Frande-Cabanes, Hector Teran-Navarro, et al.
The Oncologist|January 12, 2012
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD studyEduardo Díaz-Rubio, Auxiliadora Gómez-España, Bartomeu Massutí, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumabCarlos Gomez-Martin, Jose Carlos Plaza, Roberto Pazo-Cid, et al.
ESMO Open|November 5, 2020
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trialEnrique Aranda, Jose Maria Viéitez, Auxiliadora Gómez-España, et al.
The Lancet. Oncology|October 24, 2023
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Do-Youn Oh, Patricio Yañez, et al.
Pageof 20